BMC Cancer

Table 2 Roche COBAS and linear array genotyping agreement at baseline

From: Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial

Linear array	COBAS
	HPV 16 n = 6,172					HPV 18 n = 6,171^a					Other high risk HPV n = 6,171^a
	Pos	Neg	Overall agreement (95 % CI)	Kappa (95 % CI)	Pos agreement (95 % CI)	Pos	Neg	Overall agreement (95 % CI)	Kappa (95 % CI)	Pos agreement (95 % CI)	Pos	Neg	Overall agreement (95 % CI)	Kappa (95 % CI)	Pos agreement (95 % CI)
Pos	114	20	99.4 % (99.2 – 99.6)	0.87 (0.82 – 0.91)	87.0 % (82.7 – 91.4)	42	9	99.8 % (99.6 – 99.9)	0.86 (0.79 – 0.94)	86.6 % (79.4 – 93.8)	388	80	97.9 % (97.5 – 98.2)	0.85 (0.82 – 0.87)	85.7 % (83.3 – 88.2)
Neg	14	6,024	99.4 % (99.2 – 99.6)	0.87 (0.82 – 0.91)	87.0 % (82.7 – 91.4)	4	6,116	99.8 % (99.6 – 99.9)	0.86 (0.79 – 0.94)	86.6 % (79.4 – 93.8)	49	5,654	97.9 % (97.5 – 98.2)	0.85 (0.82 – 0.87)	85.7 % (83.3 – 88.2)

^aOne COBAS HPV 16 positive sample had invalid HPV 18 and Other High Risk HPV results (i.e., no beta-globin detected in the specimen)
Abbreviations: COBAS Roche cobas® 4800 HPV test, CI confidence interval

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com